Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCAX NASDAQ:LIMN NASDAQ:MRVI NASDAQ:RLAY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCAXBicara Therapeutics$10.53-5.2%$10.31$7.80▼$28.09$605.90MN/A309,275 shs409,857 shsLIMNLiminatus Pharma$5.93-5.4%$0.00$4.40▼$33.66$163.11MN/A982,702 shs171,387 shsMRVIMaravai LifeSciences$2.22-5.1%$2.40$1.66▼$9.95$595.90M0.281.51 million shs1.18 million shsRLAYRelay Therapeutics$3.36-4.5%$3.42$1.77▼$10.72$603.49M1.622.64 million shs2.79 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCAXBicara Therapeutics-5.22%-10.38%+14.46%-27.38%+1,052,999,900.00%LIMNLiminatus Pharma-5.42%-31.92%-32.69%+592,999,900.00%+592,999,900.00%MRVIMaravai LifeSciences-5.13%-17.47%-16.23%+7.25%-77.18%RLAYRelay Therapeutics-4.55%-10.16%-6.67%+3.38%-59.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCAXBicara TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ALIMNLiminatus PharmaN/AN/AN/AN/AN/AN/AN/AN/AMRVIMaravai LifeSciences3.7585 of 5 stars3.11.00.04.42.70.81.3RLAYRelay Therapeutics1.9652 of 5 stars3.40.00.00.02.32.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCAXBicara Therapeutics 3.00Buy$31.86202.55% UpsideLIMNLiminatus Pharma 0.00N/AN/AN/AMRVIMaravai LifeSciences 2.25Hold$6.64199.05% UpsideRLAYRelay Therapeutics 2.83Moderate Buy$17.67425.79% UpsideCurrent Analyst Ratings BreakdownLatest LIMN, MRVI, RLAY, and BCAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025BCAXBicara TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderweight ➝ Equal Weight$8.005/23/2025BCAXBicara TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$30.005/16/2025BCAXBicara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$44.00 ➝ $41.005/13/2025MRVIMaravai LifeSciencesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $10.005/13/2025MRVIMaravai LifeSciencesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$3.00 ➝ $2.005/7/2025RLAYRelay TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $10.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCAXBicara TherapeuticsN/AN/AN/AN/A$9.04 per shareN/ALIMNLiminatus PharmaN/AN/AN/AN/AN/AN/AMRVIMaravai LifeSciences$259.18M2.18$0.59 per share3.79$2.28 per share0.97RLAYRelay Therapeutics$10.01M57.55N/AN/A$4.65 per share0.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCAXBicara Therapeutics-$68MN/A0.00N/AN/AN/AN/AN/A8/12/2025 (Estimated)LIMNLiminatus PharmaN/AN/A0.00∞N/AN/AN/AN/AN/AMRVIMaravai LifeSciences-$144.85M-$1.14N/AN/AN/A-67.14%-12.91%-6.87%8/11/2025 (Estimated)RLAYRelay Therapeutics-$337.71M-$2.23N/AN/AN/AN/A-44.17%-39.53%8/7/2025 (Estimated)Latest LIMN, MRVI, RLAY, and BCAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025BCAXBicara Therapeutics-$0.54N/AN/AN/AN/AN/A8/11/2025Q2 2025MRVIMaravai LifeSciences-$0.06N/AN/AN/A$47.46 millionN/A8/7/2025Q2 2025RLAYRelay Therapeutics-$0.49N/AN/AN/A$0.07 millionN/A5/13/2025Q1 2025BCAXBicara Therapeutics-$0.40-$0.68-$0.28-$0.68N/AN/A5/12/2025Q1 2025MRVIMaravai LifeSciences-$0.07-$0.08-$0.01-$0.21$44.01 million$46.85 million5/5/2025Q1 2025RLAYRelay Therapeutics-$0.50-$0.46+$0.04-$0.46$0.01 million$7.68 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCAXBicara TherapeuticsN/AN/AN/AN/AN/ALIMNLiminatus PharmaN/AN/AN/AN/AN/AMRVIMaravai LifeSciencesN/AN/AN/AN/AN/ARLAYRelay TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCAXBicara TherapeuticsN/A24.6224.62LIMNLiminatus PharmaN/AN/AN/AMRVIMaravai LifeSciences0.605.965.17RLAYRelay TherapeuticsN/A19.9619.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCAXBicara TherapeuticsN/ALIMNLiminatus PharmaN/AMRVIMaravai LifeSciences50.25%RLAYRelay Therapeutics96.98%Insider OwnershipCompanyInsider OwnershipBCAXBicara Therapeutics15.50%LIMNLiminatus PharmaN/AMRVIMaravai LifeSciences2.11%RLAYRelay Therapeutics4.87%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCAXBicara Therapeutics3254.54 million46.08 millionN/ALIMNLiminatus PharmaN/A26.02 millionN/AN/AMRVIMaravai LifeSciences610254.66 million249.29 millionOptionableRLAYRelay Therapeutics330171.45 million163.10 millionOptionableLIMN, MRVI, RLAY, and BCAX HeadlinesRecent News About These CompaniesRelay Therapeutics: What's Next For H2 2025?1 hour ago | seekingalpha.comBrokerages Set Relay Therapeutics, Inc. (NASDAQ:RLAY) Target Price at $17.67August 2 at 2:21 AM | americanbankingnews.comBarclays Reiterates a Buy Rating on Relay Therapeutics (RLAY)August 1 at 2:18 AM | msn.comInsider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Sells 4,069 Shares of StockJuly 31 at 8:04 PM | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Insider Peter Rahmer Sells 15,724 SharesJuly 31 at 8:04 PM | marketbeat.comInsider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Sells 18,276 Shares of StockJuly 31 at 8:03 PM | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 18,380 SharesJuly 31 at 8:03 PM | marketbeat.comDonald A. Bergstrom Sells 26,701 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) StockJuly 31 at 7:37 PM | marketbeat.comRelay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025July 31 at 4:05 PM | globenewswire.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Insider Sells $15,218.06 in StockJuly 31 at 7:01 AM | insidertrades.comRelay Therapeutics (RLAY) to Release Quarterly Earnings on TuesdayJuly 30 at 8:18 AM | marketbeat.comRelay Therapeutics has positive read from Celcuity data, says BarclaysJuly 30 at 7:30 AM | finance.yahoo.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from AnalystsJuly 30 at 2:45 AM | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Sees Large Volume Increase - Still a Buy?July 25, 2025 | marketbeat.comRXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?July 25, 2025 | zacks.comRelay Therapeutics (NASDAQ:RLAY) Shares Up 5.6% - Should You Buy?July 16, 2025 | marketbeat.comPrivate Capital Advisors Inc. Acquires Shares of 100,000 Relay Therapeutics, Inc. (NASDAQ:RLAY)July 14, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sanjiv Patel Sells 61,379 SharesJuly 11, 2025 | insidertrades.comSanjiv Patel Sells 61,379 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) StockJuly 10, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 5, 2025 | marketbeat.comRelay Therapeutics, Inc. (RLAY) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLIMN, MRVI, RLAY, and BCAX Company DescriptionsBicara Therapeutics NASDAQ:BCAX$10.53 -0.58 (-5.22%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.05 -0.48 (-4.56%) As of 08/1/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.Liminatus Pharma NASDAQ:LIMN$5.93 -0.34 (-5.42%) As of 08/1/2025 04:00 PM EasternLiminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.Maravai LifeSciences NASDAQ:MRVI$2.22 -0.12 (-5.13%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.22 +0.00 (+0.23%) As of 08/1/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.Relay Therapeutics NASDAQ:RLAY$3.36 -0.16 (-4.55%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.36 0.00 (0.00%) As of 08/1/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
